A.R.T. Advisors’s Cellectar Biosciences CLRB Stock Holding History

A.R.T. Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5	Closed	-$24K	–	1385
2017 Q2	$24K	Buy	+5	New	+$27.4K	﹤0.01%	1338

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIM

Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return

WAM

Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

A.R.T. Advisors's CLRB Position: Q3 2017 in Review

A.R.T. Advisors sold out of Cellectar Biosciences (CLRB) in Q3 2017, closing a stake of 5 shares — an estimated $24K sold.

A.R.T. Advisors first reported a position in CLRB in Q2 2017 and held it in 1 quarter. The position peaked at $24K in Q2 2017. 8 funds tracked by Wall St. Rank hold CLRB as of Q3 2017.

A.R.T. Advisors reported no remaining Cellectar Biosciences position as of Q3 2017 after selling out during the quarter.
A.R.T. Advisors sold 5 Cellectar Biosciences shares in Q3 2017, an estimated $24K.
A.R.T. Advisors first reported a position in Cellectar Biosciences in Q2 2017 and held it in 1 quarter.
A.R.T. Advisors's Cellectar Biosciences position peaked at $24K in Q2 2017.
8 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2017.

Based on A.R.T. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.